Congress froze the Ryan White dollar. The caseload didn't.

The Ryan White HIV/AIDS Program is the federal payer of last resort for HIV care: it funds the clinics, case managers, and drug-assistance programs that catch people who fall outside private insurance and Medicaid.▸ Its budget doesn't move much year to year — appropriators tend to treat it as untouchable. In 2025 that assumption was tested directly, and the program came out with the same number on the check it's had since 2024.

The program isn't one grant — it's four statutory "parts," plus a scientific-innovation fund and a slice of the Ending the HIV Epidemic initiative, all appropriated under a single Ryan White heading.▸ Part B, which flows to states and includes the AIDS Drug Assistance Program (ADAP), is the largest single piece at more than half the total. Part A goes to the metro areas hit hardest by the epidemic. Parts C, D, and F fund early-intervention clinics, services for women and children, and the clinician-training pipeline, respectively.

The total — $2,571,041,000 — is not a new number.▸ It is the exact same figure Congress enacted for FY2024 and FY2025. Three budget cycles running, the Ryan White line has not grown by a single dollar.

Flat funding was not the worst outcome on the table.▸ The House Appropriations Committee's FY2026 Labor-HHS-Education subcommittee mark, released September 1, 2025, funded only Parts A and B under the "Ryan White HIV/AIDS Program" heading — $2,045,630,000, with no separate line anywhere in the bill for Parts C, D, or F, the training-center program, or the Ending the HIV Epidemic initiative. Effectively, those pieces were zeroed out: a $525,411,000 reduction, about a fifth of the enacted program.

That mark never became law.▸ The final FY2026 Labor-HHS bill, signed February 3, 2026, kept Ryan White whole — the Senate Appropriations Committee's own summary describes the enacted bill as rejecting "House Republicans' proposal to cut HIV/AIDS programs by over $1.5 billion." Congress restored the money. It did not add to it.

While that fight played out, the program's caseload kept climbing.▸ HRSA's 2024 Annual Data Report counted 601,853 clients served that year — the most in the program's 35-year history, and more than 40,000 above the 2020 total, on an appropriation that hasn't grown since 2024.

The clinical case for the program is, by HRSA's own numbers, getting stronger, not weaker: 91.4% of RWHAP patients receiving HIV medical care in 2024 reached viral suppression — up from 69.5% in 2010, and well above the 67.2% viral-suppression rate among all diagnosed people with HIV nationally, RWHAP clients included.▸ A larger caseload is also a more effectively treated one.

Even with the total protected, how that total is divided is about to shift.▸ HRSA announced that starting in FY2026, Parts A and B formula awards will phase, over five years ending in FY2030, from counting living HIV cases by location at diagnosis to counting them by a patient's most recent address. The stated rationale is that current addresses better reflect where people actually receive care today. The practical effect is that jurisdictions where people were diagnosed years ago but have since moved will see their formula share shrink, while jurisdictions gaining population will see theirs grow — the same $2.571 billion, reshuffled by geography, phased in gradually enough that "no one loses money overnight," but with every recipient's five-year trajectory now pointed by a different number.

Appropriations figures are enacted, full-year totals as reported by HRSA; the House figure is a committee-level proposal that did not become law. Client and viral-suppression figures cover calendar year 2024, the most recent year in HRSA's Annual Data Report.